| Literature DB >> 35836184 |
Alaa Mabrouk Salem Omar1,2,3, Diana Maria Ronderos Botero4, Javier Arreaza Caraballo5, Ga Hee Kim5, Yeraz Khachatoorian5, Jaclyn Kliewer4,6, Mohamed Ahmed Abdel Rahman7, Osama Rifaie7, Jonathan N Bella8,4, Edgar Argulian5,8, Johanna Contreras5,8.
Abstract
BACKGROUND: Pre-(PRE) and post-ejection (POE) velocities by mitral annular tissue Doppler (TD) are biphasic and may be related to myocardial deformations. We investigated the predominance and concordance of TD-PRE and POE velocities and their effect on myocardial functions in controls and in heart failure (HF) patients.Entities:
Keywords: Heart failure; Post-ejection; Pre-ejection; Tissue doppler imaging
Mesh:
Year: 2022 PMID: 35836184 PMCID: PMC9281174 DOI: 10.1186/s12947-022-00287-0
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.263
Fig. 1Biphasic myocardial velocities during pre and post-ejection phases in controls and heart failure patients. Upper panel: Tissue Doppler-derived as well as schematic representation of tissue Doppler (TDI)-derived mitral annular velocities in normal controls. In blue, the predominantly positive biphasic pre-ejection (PRE), the positive component (PREp) predominates over the following negative component (PREn). In red, the predominantly negative biphasic post-ejection (POE), the negative component (POEn) predominates over the following positive component (POEp). Lower panel, representation of different concordance of isovolumic phases in heart failure patients, from left to right, normal concordance, predominantly positive PRE and predominantly negative POE, reversed PRE concordance, predominantly negative PRE and POE, reversed POE concordance, predominantly positive PRE and POE, totally reversed concordance, predominantly negative PRE and predominantly positive POE
Baseline demographic, clinical and echocardiographic characteristics in heart failure patients as well as normal and age matched controls
| Age, years | 58.1 ± 8.2 | 56.7 ± 8 | 27.3 ± 3.95 | 53 ± 11.474 | < 0.001 #‡€ |
| Sex, (female), n(%) | 19(37) | 9(28) | 5(12) | 17(65) | < 0.001 |
| Diabetic, n(%) | 21(40) | 11(34) | 0(0) | 0(0) | 0.009 |
| Hypertensive, n(%) | 23(44) | 12(38) | 0(0) | 8(31) | < 0.001 |
| Hyperlipidemia, n(%) | 8(15) | 3(9) | 0(0) | 1(4) | 0.292 |
| Smoker, n(%) | 14(27) | 8(25) | 0(0) | 4(15) | 0.037 |
| Coronary artery disease, n(%) | 17(33) | 16(50) | 0(0) | 2(8) | < 0.001 |
| PCI, n(%) | 8(15) | 9(19) | 0(0) | 1(4) | 0.210 |
| CABG, n(%) | 0(0) | 0(0) | 0(0) | 0(0) | 1.000 |
| NYHA (1/2/3/4), n(%) | 4(8)/31(60)/15(29)/0(0) | 1(3)/18(56)/11(34)/2(6) | - | - | |
| E (cm/s) | 75 ± 27 | 88.7 ± 21.5 | 82.7 ± 16.7 | 71 ± 18.5 | 0.011*$ |
| A (cm/s) | 81.8 ± 20.7 | 71.2 ± 33.8 | 56 ± 8.1 | 76.2 ± 21.6 | < 0.001¶€ |
| EDV (ml) | 99.2 ± 21.7 | 152.5 ± 54.3 | 95.4 ± 17.8 | 87.8 ± 19.3 | < 0.001*‡$ |
| ESV (ml) | 35.4 ± 10.3 | 96.2 ± 49.8 | 32.2 ± 7.7 | 30.7 ± 10 | < 0.001*‡$ |
| EF (%) | 65 ± 5.1 | 38.9 ± 9.2 | 66.3 ± 5.1 | 61.5 ± 4.7 | < 0.001*‡$€ |
| e'-septal (cm/s) | 6.5 ± 1.9 | 5.6 ± 1.7 | 11 ± 2.4 | 8.6 ± 2.3 | < 0.001#¶‡$€ |
| S'-Septal (cm/s) | 7.5 ± 1.5 | 5.6 ± 1.8 | 8.2 ± 1.6 | 8.27 ± 1.8 | < 0.001*‡$ |
| e'-lateral (cm/s) | 8.4 ± 2.8 | 7.1 ± 2.5 | 14 ± 2.8 | 10.9 ± 2.8 | < 0.001*‡$€ |
| S'-lateral (cm/s) | 7.9 ± 2 | 6.2 ± 1.8 | 10.1 ± 2 | 8.9 ± 1.9 | < 0.001*#‡$ |
| e'-mean (cm/s) | 7.5 ± 2.2 | 6.3 ± 1.9 | 12.5 ± 2.5 | 9.8 ± 2.4 | < 0.001#¶‡$€ |
| S’-mean (cm/s) | 7.7 ± 1.5 | 5.9 ± 1.5 | 9.2 ± 1.6 | 8.5 ± 1.6 | < 0.001*#‡$ |
| E/A | 0.96 ± 0.45 | 1.41 ± 0.77 | 1.52 ± 0.41 | 0.96 ± 0.25 | < 0.001*#$€ |
| E/e' | 10.7 ± 4.4 | 14.6 ± 4.55 | 6.63 ± 0.83 | 7.6 ± 1.73 | < 0.001*#¶‡$ |
| PREp (septal), (cm/s) | 6.8 ± 2.2 | 4.5 ± 1.9 | 7.9 ± 2.3 | 7.8 ± 2.1 | < 0.001*‡$ |
| PREn (septal), (cm/s) | 3.3 ± 1.6 | 3.1 ± 1.5 | 3 ± 1.3 | 3.1 ± 1.3 | 0.793 |
| POEn (septal), (cm/s) | 3.3 ± 1.1 | 2.6 ± 0.98 | 4.5 ± 1 | 4.2 ± 1.2 | < 0.001*#¶‡$ |
| POEp (septal), (cm/s) | 2.6 ± 0.8 | 2.7 ± 1.5 | 1.9 ± 0.7 | 2.1 ± 0.6 | 0.002#‡ |
| PREp (lateral), (cm/s) | 5.7 ± 2.5 | 4.1 ± 1.4 | 6.8 ± 1.8 | 7.5 ± 2.4 | < 0.001*¶‡$ |
| PREn (lateral), (cm/s) | 4 ± 1.2 | 3.5 ± 1.8 | 3.2 ± 1.4 | 3 ± 1.08 | 0.014¶ |
| POEn (lateral), (cm/s) | 3.3 ± 1.1 | 2.3 ± 0.8 | 4.8 ± 1.6 | 3.5 ± 1.1 | < 0.001*#‡$€ |
| POEp (lateral), (cm/s) | 2.7 ± 0.8 | 2.9 ± 0.9 | 2.1 ± 0.7 | 2.1 ± 0.6 | < 0.001#¶‡$ |
| PREp (mean), (cm/s) | 6.3 ± 2.2 | 4.3 ± 1.6 | 7.1 ± 1.7 | 7.2 ± 1.9 | < 0.001*‡$ |
| PREn (mean), (cm/s) | 3.7 ± 1.1 | 3.3 ± 1.4 | 3.1 ± 0.96 | 2.9 ± 0.8 | 0.016¶ |
| POEn (mean), (cm/s) | 3.3 ± 1 | 2.4 ± 0.7 | 3.9 ± 1.4 | 3.7 ± 0.9 | < 0.001*#‡$ |
| POEp (mean), (cm/s) | 2.6 ± 0.7 | 2.8 ± 0.99 | 2.6 ± 1.2 | 1.98 ± 0.63 | 0.005¶€ |
| PREp/PREn (PRE-P/N) | 1.8 ± 0.7 | 1.5 ± 1.03 | 2.5 ± 1.05 | 2.6 ± 0.7 | < 0.001#¶‡$ |
| POEn/POEp (POE-N/P) | 1.3 ± 0.5 | 1.1 ± 1.04 | 2.2 ± 1.07 | 2.1 ± 1.3 | < 0.001#¶‡$ |
| PREp-mean/S’-mean | 0.82 ± 0.3 | 0.7 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.22 | 0.182 |
| LBBB, n(%)(**) | 1(2%) | 7(22%) | 0(0%) | 0(0%) | 0.519 |
| RBBB, n(%)(**) | 3(6%) | 0(0%) | 0(0%) | 1(4%) | 0.626 |
| IVCD, n(%)(**) | 0(0%) | 4(13%) | 0(0%) | 0(0%) | 0.041 |
| QRS duration, ms | 84.4 ± 12.7 | 96.2 ± 24 | 72.6 ± 11 | 79.2 ± 18 | < 0.001*‡$ |
* p < 0.05 between HFpEF and HFrE
# P < 0.05 between HFpEF and normal
¶ p < 0.05 between HFpEF and Controls
‡ p < 0.05 between HFrEF and norma
$ p < 0.05 between HFrEF and Controls
€ p < 0.05 between normal and controls. PREp, positive pre-ejection, PREn, negative pre-ejection, POEn, negative post-ejection, POEp, positive post-ejection. PREp, positive pre-ejection, PREn, negative pre-ejection, POEn, negative post-ejection, POEp, positive post-ejection
Fig. 2Frequency of predominance of biphasic tissue Doppler mitral annular velocities during pre (PRE) and post-ejection (POE) phases, and their concordance. Upper panel, in normal as well as age matched controls, PRE is almost always predominantly positive (PREp > PREn), while more patients with negative predominance (PREn > PREp) occurs in HFpEF and the largest number occurs in patients with HFrEF. Similarly, in normal as well as age matched controls, POE is almost always predominantly negative (POEn > POEp), while more patients with positive predominance (POEp > POEn) occurs in HFpEF and the largest number occurs in patients with HFrEF. Lower panel, Normal PRE-POE concordance (predominantly positive PRE and predominantly negative POE) occurs almost always in normal as well as the aged matched controls. In patients with HFpEF, lower number of normal concordance and increasing number of PRE reversed and POE reversed as well as totally reversed concordance was noted. In patients with HFrEF, the lowest number of normal concordance, and the largest number of totally reversed concordance was observed
Comparison of study subjects based on PRE-POE concordance
| Age, years | 46.7 ± 15.4 | 53 ± 17.9 | 57.4 ± 6.92 | 58.9 ± 9.6 | < 0.001#¶ |
| Sex, (female), n(%) | 29 | 2 | 12 | 6 | 0.671 |
| HFpEF/HFrEF/ Normal/Control, n(%) | 28/6/39/23 | 4/0/1/0 | 17/12/1/1 | 3/13/1/0 | < 0.001 |
| NYHA (I/II/III/IV), n(%) | 3/24/6/1 | 0/2/2/0 | 3/16/9/0 | 0/7/9/0 | 0.015 |
| NYHA (mean ± SD) | 1.6 ± 1 | 2 ± 1.2 | 2.2 ± 0.6 | 2.6 ± 0.5 | 0.001#¶ |
| E (cm/s) | 74.3 ± 19.1 | 95.4 ± 25.9 | 80.6 ± 23.2 | 97.5 ± 30.7 | 0.001¶ |
| A (cm/s) | 71.9 ± 22.7 | 68.3 ± 17.5 | 85.8 ± 25.1 | 62.1 ± 27.3 | 0.01#€ |
| EDV (ml) | 98.1 ± 24.6 | 113.7 ± 29.7 | 115.7 ± 37.57 | 158.5 ± 67.1 | < 0.001¶$€ |
| ESV (ml) | 36.8 ± 18.6 | 36.4 ± 3.5 | 57.4 ± 36.4 | 98 ± 66.7 | < 0.001¶$€ |
| EF (%) | 62.8 ± 8.7 | 67 ± 4.9 | 56.4 ± 14 | 44.1 ± 14.9 | < 0.001#¶$€ |
| e'-mean (cm/s) | 9.8 ± 3.1 | 8.5 ± 4.1 | 7 ± 1.9 | 6 ± 1.9 | < 0.001#¶ |
| S’-mean (cm/s) | 8.3 ± 1.8 | 8.6 ± 1.8 | 7.3 ± 1.9 | 5.8 ± 1.15 | < 0.001¶$ |
| E/A | 1.1 ± 0.4 | 1.53 ± 0.73 | 0.98 ± 0.4 | 1.7 ± 0.87 | < 0.001¶€ |
| E/e' | 7.9 ± 2.4 | 12.8 ± 5.4 | 12.2 ± 3.7 | 17.1 ± 5.3 | < 0.001#¶€ |
| PREp (mean), (cm/s) | 6.9 ± 1.9 | 4.4 ± 0.97 | 5.9 ± 1.9 | 3.3 ± 1.1 | < 0.001*#¶€ |
| PREn (mean), (cm/s) | 3.1 ± 0.9 | 4.6 ± 1.1 | 3.7 ± 1.3 | 3.8 ± 1.4 | < 0.001*#¶ |
| POEn (mean), (cm/s) | 3.8 ± 1.1 | 3.2 ± 0.6 | 2.6 ± 0.9 | 2.2 ± 0.6 | < 0.001#¶ |
| POEp (mean), (cm/s) | 2.3 ± 0.87 | 1.9 ± 0.5 | 2.97 ± 0.82 | 3.3 ± 0.9 | < 0.001#¶‡$€ |
| PREp /PREn (PRE-P/N ratio) | 2.4 ± 0.97 | 0.98 ± 0.2 | 1.64 ± 0.56 | 0.9 ± 0.17 | < 0.001*#¶€ |
| POEn/POEp (POE-N/P ratio) | 2.1 ± 1.1 | 1.7 ± 0.5 | 0.87 ± 0.19 | 0.68 ± 0.21 | < 0.001#¶ |
| PREp-mean/S’-mean | 0.87 ± 0.3 | 0.5 ± 0.1 | 0.8 ± 0.2 | 0.61 ± 0.17 | < 0.001*¶ |
| QRS duration, ms (**) | 79.5 ± 19.7 | 73.6 ± 3.1 | 87.4 ± 23.4 | 98.4 ± 23.2 | 0.028*# |
| LBBB, n(%)(**) | 2(6%) | 0(0%) | 3(10%) | 3(18%) | 0.519 |
| RBBB, n(%)(**) | 1(3%) | 0(0%) | 2(7%) | 0(0%) | 0.626 |
| IVCD, n(%)(**) | 0(0%) | 0(0%) | 1(3%) | 3(18%) | 0.041 |
* p < 0.05 between Normal and IC reversed
# P < 0.05 Normal and IR reversed
¶ p < 0.05 between Normal and totally reversed
‡ p < 0.05 between IC reversed and IR reversed
$ p < 0.05 between IC reversed and totally reversed
€ p < 0.05 between IR reversed and totally reversed
(**) calculated from patients with heart failure
PREp positive pre-ejection, PREn negative pre-ejection, POEn negative post-ejection, POEp positive post-ejection LBBB left bundle branch block, RBBB right bundle branch block, IVCD intra-ventricular consuction delay
Correlations observed in our study
| 0.561 | < 0.001 | 0.421 | 0.018 | 0.521 | < 0.001 | 0.786 | < 0.001 | |
| 0.425 | 0.005 | 0.611 | < 0.001 | 0.253 | 0.107 | 0.419 | 0.042 | |
| 0.292 | 0.036 | 0.896 | < 0.001 | 0.736 | < 0.001 | 0.483 | 0.019 | |
| 0.513 | < 0.001 | 0.4 | 0.025 | 0.04 | 0.843 | 0.02 | 0.928 | |
| 0.07 | 0.609 | 0.144 | 0.439 | 0.177 | 0.377 | 0.06 | 0.770 | |
| 0.432 | 0.002 | 0.256 | 0.165 | 0.142 | 0.481 | 0.04 | 0.853 | |
| 0.136 | 0.342 | 0.363 | 0.045 | 0.174 | 0.385 | 0.042 | 0.844 | |
| 0.55 | < 0.001 | 0.54 | 0.002 | 0.20 | 0.315 | 0.06 | 0.774 | |
| 0.3 | 0.034 | 0.45 | 0.012 | 0.225 | 0.259 | 0.05 | 0.800 | |
| 0.068 | 0.631 | 0.413 | 0.021 | 0.022 | 0.888 | 0.253 | 0.211 | |
| 0.075 | 0.596 | 0.189 | 0.308 | 0.232 | 0.139 | 0.172 | 0.400 | |
| 0.169 | 0.230 | 0.290 | 0.113 | 0.085 | 0.59 | 0.366 | 0.07 | |
| 0.084 | 0.552 | 0.173 | 0.353 | 0.211 | 0.180 | 0.202 | 0.323 | |
| 0.116 | 0.414 | 0.230 | 0.222 | 0.225 | 0.152 | 0.103 | 0.631 | |
| 0.045 | 0.750 | 0.036 | 0.849 | 0.180 | 0.255 | 0.106 | 0.940 | |
PREp positive pre-ejection, PREn negative pre-ejection, POEn negative post-ejection, POEp positive post-ejection
Fig. 3Dot plots for correlations observed in our study in subgroups. Upper panel: correlation between opposite waves of the biphasic PRE velocities (left: between positive PRE and negative POE, right: between negative PRE and positive POE). Middle panel: correlation between the ratio of positive to negative PRE waves (PRE-P/N) vs, the negative to positive POE (POE-N/P). Lower panel: correlations against E/e’ as a representation of LV filling pressures (left: versus the PRE-P/N ratio, right: versus the POE-N/P ratio)
Fig. 4Receiver operator characteristic curves (ROC-curves) for best predictors of E/e’ ≥ 13 in patients with heart failure. Black line, positive PRE and negative PRE (PRE-P/N) ratio, red line, between negative POE to positive POE (POE-N/P) ratio
Reproducibility analyses
| 0.94 | < 0.001 | 0.03 ± 0.93 | 0.97 | < 0.001 | 0.11 ± 0.57 | |
| 0.84 | < 0.001 | -0.72 ± 0.67 | 0.93 | < 0.001 | -0.22 ± 0.45 | |
| 0.91 | < 0.001 | -0.53 ± 0.38 | 0.93 | < 0.001 | -0.17 ± 0.31 | |
| 0.88 | < 0.001 | 0.01 ± 0.38 | 0.89 | < 0.001 | 0.02 ± 0.34 | |
PREp positive pre-ejection, PREn negative pre-ejection, POEn negative post-ejection, POEp positive post-ejection